J
Jan Van Droogenbroeck
Publications - 21
Citations - 725
Jan Van Droogenbroeck is an academic researcher. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 6, co-authored 14 publications receiving 638 citations.
Papers
More filters
Journal ArticleDOI
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian,Neil P. Shah,Jorge E. Cortes,Michele Baccarani,Mohan B. Agarwal,Maria Soledad Undurraga,Jianxiang Wang,Juan Julio Kassack Ipiña,Dong-Wook Kim,Michinori Ogura,Carolina Pavlovsky,Christian Junghanss,Jorge Milone,Franck E. Nicolini,Tadeusz Robak,Jan Van Droogenbroeck,Edo Vellenga,M. Brigid Bradley-Garelik,Chao Zhu,Andreas Hochhaus +19 more
TL;DR: Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR).
Journal ArticleDOI
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
Charles Dumontet,Cyrille Hulin,Meletios A. Dimopoulos,Andrew Belch,Angela Dispenzieri,Heinz Ludwig,Philippe Rodon,Jan Van Droogenbroeck,Lugui Qiu,Michele Cavo,Ann Van de Velde,Juan José Lahuerta,Olivier Allangba,Jae Hoon Lee,Eileen M Boyle,Aurore Perrot,Philippe Moreau,Salomon Manier,Michel Attal,Murielle Roussel,Mohamad Mohty,Jean Yves Mary,Alexandre Civet,Bruno M. Costa,Antoine Tinel,Yann Gaston-Mathé,Thierry Facon +26 more
TL;DR: A predictive model of early TE grade ≥ 3 infection in the first 4 months may be applied in the clinical setting to guide infection monitoring and strategies for infection prevention.
Journal ArticleDOI
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Markus Hansson,Peter Gimsing,Ashraf Badros,Titti Martinsson Niskanen,Hareth Nahi,Fritz Offner,Morten Salomo,Elisabeth Sonesson,Morten Mau-Sørensen,Yvonne Stenberg,Annika Sundberg,Ingrid Teige,Jan Van Droogenbroeck,Stina Wichert,Maurizio Zangari,Björn Frendéus,Magnus Korsgren,Martine Poelman,Guido Tricot +18 more
TL;DR: BI-505′s half-life increased with dose while clearance decreased, suggesting target-mediated clearance, and can be safely administered at doses that saturate myeloma cell ICAM-1 receptors in patients.
Journal ArticleDOI
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
Katja Weisel,Chantal Doyen,Meletios A. Dimopoulos,Adrian Yee,Juan José Lahuerta,Amber Martin,Karin Travers,Eric Druyts,Kabirraaj Toor,Niels Abildgaard,Jin Lu,Jan Van Droogenbroeck,Catarina Geraldes,Mario Petrini,Laurent Voillat,Eric Voog,Thierry Facon +16 more
TL;DR: A network meta-analysis using RCTs identified through a systematic literature review to evaluate the relative efficacy of Rd versus other regimens on survival endpoints in previously untreated MM patients ineligible for ASCT found Rd was associated with a significant PFS and survival advantage versus other first-line treatments.
Journal ArticleDOI
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015
Antonio Palumbo,Zdenek Adam,Martin Kropff,Robin Foà,John G. Catalano,Heinz Gisslinger,Wieslaw Wiktor-Jedrzejczak,Michel Delforge,Katja Weisel,Nicola Cascavilla,Jan Van Droogenbroeck,Genadi Iosava,Michele Cavo,Joan Bladé,Meral Beksac,Ivan Spicka,Torben Plesner,Zhinuan Yu,Lindsey Herbein,Jay Mei,Christian Jacques,Meletios A. Dimopoulos +21 more
TL;DR: Palumbo et al. as discussed by the authors compared MPR-R with fixed-duration MPR and MP induction in transplant-ineligible NDMM patients, and found that MPR induction alone provided a significant PFS benefit vs MP (15 vs 12 mos; HR: 0.64 [95% CI, 0.45-0.90]